X

Trial Profile

A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Tianjin CanSino Biotechnology

Most Recent Events

30 Jun 2020 Planned End Date changed from 1 Aug 2021 to 30 Dec 2021.
30 Jun 2020 Planned primary completion date changed from 1 Mar 2021 to 20 Dec 2021.
30 Jun 2020 Planned initiation date changed from 1 May 2020 to 1 Aug 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com